Commentary Open Access
Volume 4 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.4.064
Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer?
Devavrat Tripathi1,2, Savita Kulkarni1,2,*
- 1Radiation Medicine Centre, Bhabha Atomic Research Centre, c/o TMH Annexe, Parel, Mumbai, India
- 2Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, India
Corresponding Author
Savita Kulkarni, savita.kulkarni1@gmail.com; savitapk@barc.gov.in
Received Date: April 19, 2022
Accepted Date: August 04, 2022
Tripathi D, Kulkarni S. Can Butein be a Future Candidate for the Treatment of Advance Metastatic Thyroid Cancer? J Cancer Immunol. 2022;4(2):43-46.
Copyright: © 2022 Tripathi D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Botulinum Toxin: The Promising Future of Prostate Cancer Treatment
Botulinum toxin (BT) is a potent poisonous neurotoxin produced by the bacterium Clostridium botulinum and related species [1]. Its action consists of inhibiting neuromuscular junctions by blocking the release of acetylcholine and desensitizing sensory nerves.
NOXA the BCL-2 Family Member behind the Scenes in Cancer Treatment
NOXA is a critical mediator of stress responses to anticancer drugs. This BH3-only protein sets the apoptotic threshold in cancer cells in response to chemotherapies by counteracting the prosurvival BCL-2 family protein MCL-1. A complex and dynamic network relying on both highly controlled gene transcription activity and protein degradation by proteasome, regulates cellular NOXA levels from low in steady state to rapidly enhanced upon stressful condition.
Thyroid Hormones in Dilated Cardiomyopathy: Is It a Promising Therapeutic Option?
Dilated cardiomyopathy (DCM) is chronic heart muscle disease characterized by progressive ventricular enlargement and contractile dysfunction involving either left or both ventricles. It is considered one of the leading causes of heart failure with reduced ejection fraction (HFrEF) worldwide
Clinician's Review of Thyroid and Parathyroid Disease
The presentation of thyroid disease is on a spectrum with clinical presentations and disease severity ranging from subclinical to critical. The principal function of the thyroid gland is to produce T3 (triiodothyronine) and T4 (thyroxine). The hypothalamus and pituitary glands release thyrotropin releasing hormone (TRH) and thyroid stimulating hormone (TSH) respectively, and this stimulates the release of T3 and T4 directly from the thyroid gland.
Relevance of Neuropilin 1 and Neuropilin 2 Targeting for Cancer Treatment
Neuropilins (NRPs) are a class of transmembrane glycoprotein co-receptors including Neuropilin 1 (NRP1) and Neuropilin 2 (NRP2). They are the co-receptors of different families of receptors, thus they are involved in many hallmarks of cancer.